Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.5.0.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents [note 4] $ 11,800 $ 34,310
Short-term investments [note 4] 20,655 20,876
Interest receivable 36 111
Prepaid expenses 1,647 1,987
Other current assets 158 14
Total current assets 34,296 57,298
Restricted cash [note 4 and note 7] 272 272
Property and equipment, net 493 602
Other assets 13 37
Total assets 35,074 58,209
Current liabilities:    
Accounts payable 1,043 1,343
Accrued liabilities other 602 641
Accrued clinical liabilities 7,114 9,966
Accrued compensation 1,422 1,267
Current portion of long-term obligations [note 7] 57 52
Lease termination liability [note 7]   1,250
Deferred collaboration revenue [note 3]   5,040
Warrant liability [note 4 and note 5] 350 1,105
Total current liabilities 10,588 20,664
Long-term obligations, less current portion [note 7] 67 105
Total liabilities 10,655 20,769
Commitments and contingencies [note 7]
Stockholders' equity:    
Common stock, $0.001 par value, 75,000,000 shares authorized, 30,054,287 and 29,846,991 issued at September 30, 2016 and December 31, 2015, respectively, and 30,020,294 and 29,812,998 outstanding at September 30, 2016 and December 31, 2015, respectively 30 29
Additional paid-in capital 212,843 211,590
Accumulated deficit (191,097) (176,811)
Accumulated other comprehensive income 2,643 2,632
Total stockholders' equity 24,419 37,440
Total liabilities and stockholders' equity $ 35,074 $ 58,209